Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03423628 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

A Phase 1 study of Recurrent Glioblastoma Multiforme and Primary Glioblastoma Multiforme, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
180
Enrollment target
12
Study locations

NCT03423628 is a Phase 1 study of Recurrent Glioblastoma Multiforme and Primary Glioblastoma Multiforme that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 180 participants, above the 74-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (143% higher). The trial reports 12 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03423628, a Phase 1 study of Recurrent Glioblastoma Multiforme and Primary Glioblastoma Multiforme, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
180 participants
Enrollment target
12
Study locations

Study Summary

This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy

Conditions Studied

Recurrent Glioblastoma Multiforme Primary Glioblastoma Multiforme Brain Neoplasms, Malignant Leptomeningeal Disease (LMD)

Interventions

  • RADIATION Radiation Therapy
  • DRUG AZD1390

Study Locations (12)

Other

  • Research Site - Chūōku
  • Research Site - Hidaka-shi
  • Research Site - Kyoto
  • Research Site - Cambridge
  • Research Site - Glasgow
  • Research Site - Leeds
  • Research Site - London

Massachusetts

  • Research Site - Boston
  • Research Site - Boston

New York

  • Research Site - New York

Pennsylvania

  • Research Site - Pittsburgh

Virginia

  • Research Site - Richmond

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2018-04-02
Est. Completion 2026-09-16
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03423628

The ClinicalTrials.gov registry entry for NCT03423628 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 74-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (143% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Recurrent Glioblastoma Multiforme appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.

NCT03423628 reports 12 study locations spanning 5 distinct geographic areas - top geographies include Other, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT03423628 about?

NCT03423628 is a clinical study titled "A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer". This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of a...

What is the current status of trial NCT03423628?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2018-04-02. Estimated completion is 2026-09-16.

What conditions does trial NCT03423628 study?

This clinical trial studies the following conditions: Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD).

What interventions are being tested in trial NCT03423628?

The interventions under investigation include: Radiation Therapy (RADIATION), AZD1390 (DRUG).

Who is sponsoring clinical trial NCT03423628?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03423628 being conducted?

This trial has 12 study locations across Massachusetts, New York, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Glioblastoma Multiforme

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Glioblastoma Multiforme

All registered trials for this condition

Primary Glioblastoma Multiforme

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.